Actively Recruiting
Phase 1 Study of External Radiation and 177Lu-DOTATATE Therapy for Large Unresectable Gastrointestinal Neuroendocrine Tumors
Led by Emory University · Updated on 2026-03-02
15
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a combination treatment for patients with large, well-differentiated grade 1-2 digestive system neuroendocrine tumors that cannot be removed by surgery. This phase I trial evaluates the safety and effects of stereotactic body radiation therapy SBRT followed by lutetium-177 DOTATATE peptide receptor radionuclide therapy PRRT. The study aims to compare this combination approach to the standard use of PRRT alone in hopes of reducing disease progression or recurrence. Participants first receive SBRT over 5 treatment sessions to precisely target tumors while sparing healthy tissue. Then, 4 to 10 weeks later, they receive standard care 177Lu-DOTATATE through intravenous infusions every 8 weeks for a total of 4 doses, provided there is no disease progression or unacceptable side effects. Imaging scans including CT, MRI, and gallium Ga 68-DOTATATE PETCT are performed before and during treatment to monitor the tumor. During the trial, patients are closely monitored for side effects and tumor response. Follow-up visits occur at 90 days after treatment and then every 3 months for a year. Researchers measure acute toxicity within 3 months, tumor response at 3 months, progression-free survival at 12 months, and patient-reported quality of life up to 12 months. These assessments involve scans, questionnaires, and clinical evaluations to understand treatment safety and impact.
CONDITIONS
Brief Title
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Research Team
P
Pretesh Patel, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here